NEW YORK (GenomeWeb News) – BG Medicine said after the close of the market Friday that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market that it is not in compliance with one of the requirements for continued listing.

Specifically, Nasdaq said that the firm's market value of its listed securities had closed below the minimum $50 million required for continued listing for the 30 days leading up to Dec. 10. BG has until June 10, 2013, to regain compliance with the rule.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.